China Healthcare Weekly (Jan.21)-Growth Hormone VBP,Biotech Survival,Internationalization Conditions
We analyzed the impact of growth hormone/blood products VBP; the "reconsideration" of biotech IPO in primary market, survival problem of listed...
273 Views
Gushengtang IPO Trading - Priced at Top End with Lukewarm Subscription Rates
Gushengtang (GUS HK) raised around US$104m after pricing its IPO at HKD29.0/share, at the top end of the IPO price range.
385 Views
ECM Weekly (17th October 2021) - SG Lottery, GQG, Judo Bank, Vulcan Steel, Biocytogen, Kakao Pay
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
379 Views
Abbisko (和誉) IPO Trading: Poor Demand for the Early Stage R&D
We provide an update of Abbisko prior to the trading and re-iterate our view that the company is fairly valued for the early stage despite...
235 Views
Pre-IPO TransThera Sciences (Nanjing) - Insights on the Industry, the Business and the Concerns
This article mainly analyzed TransThera in terms of the industry characteristics of small molecule drug market, candidates in the pipeline (TT...
233 Views